Progenity to Report Third Quarter 2020 Financial Results and Provide Corporate Update
Progenity, Inc. (NASDAQ: PROG) will report its third quarter 2020 financial results on November 9, 2020, after market close. The event will include a conference call at 4:30 p.m. ET to discuss these results and provide a corporate update. Investors can access the call by dialing specified numbers or through a live webcast on the company's website. Progenity specializes in molecular testing products and aims to improve healthcare precision through its innovative diagnostic solutions.
- Upcoming Q3 2020 financial results expected to provide insights into business performance.
- Company known for successfully developing and commercializing molecular testing products.
- No specific financial metrics or projected guidance mentioned ahead of results.
SAN DIEGO, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it will report third quarter 2020 financial results on Monday, November 9, 2020 after the close of financial markets. Progenity’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 833-519-1237 for domestic callers and 914-800-3810 for international callers and entering the conference code: 5878610. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.progenity.com.
About Progenity
Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies. For additional information about Progenity, please visit the company’s website at www.progenity.com.
Investor Contact:
Robert Uhl
Managing Director, Westwicke ICR
ir@progenity.com
(619) 228-5886
Media Contact:
Kate Blom-Lowery
CG Life
kblomlowery@cglife.com
(858) 457-2436
FAQ
When will Progenity report Q3 2020 financial results?
How can I access the Progenity Q3 2020 earnings call?
What is Progenity's focus in the biotechnology sector?
What time will the Progenity earnings call take place?
